Literature DB >> 25318693

NF-kB1 gene expression in Down syndrome patients.

Michele Salemi1, Concetta Barone, Carmelo Romano, Francesco Scillato, Alda Ragalmuto, Salvatore Caniglia, Maria Grazia Salluzzo, Graziella Sciuto, Federico Ridolfo, Corrado Romano, Paolo Bosco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25318693     DOI： 10.1007/s10072-014-1981-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  4 in total

Review 1.  The "gene dosage effect" hypothesis versus the "amplified developmental instability" hypothesis in Down syndrome.

Authors:  M A Pritchard; I Kola
Journal:  J Neural Transm Suppl       Date:  1999

Review 2.  Anticancer therapy targeting the apoptotic pathway.

Authors:  Wei Hu; John J Kavanagh
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

Review 3.  NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases.

Authors:  X-F Sun; H Zhang
Journal:  Histol Histopathol       Date:  2007-12       Impact factor: 2.303

Review 4.  Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.

Authors:  Sören Beinke; Steven C Ley
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857
  4 in total
  3 in total

1.  Long non-coding RNA GAS5 expression in patients with Down syndrome.

Authors:  Michele Salemi; Giovanna Marchese; Angela Cordella; Rossella Cannarella; Concetta Barone; Maria Grazia Salluzzo; Aldo E Calogero; Corrado Romano
Journal:  Int J Med Sci       Date:  2020-05-23       Impact factor: 3.738

2.  Therapeutic effect of Resveratrol in the treatment of osteoarthritis via the MALAT1/miR-9/NF-κB signaling pathway.

Authors:  Guopeng Zhang; Hua Zhang; Wulin You; Xiaochen Tang; Xiufang Li; Zhengfeng Gong
Journal:  Exp Ther Med       Date:  2020-01-24       Impact factor: 2.447

3.  Down's syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach.

Authors:  Marcos Altable; Juan Moisés de la Serna
Journal:  Neurol Sci       Date:  2020-11-24       Impact factor: 3.307
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.